Home / Business and Economy / OneSource Pharma Q1 Revenue Soars 37%
OneSource Pharma Q1 Revenue Soars 37%
25 Jul
Summary
- First-quarter revenue increased 37%, driven by semaglutide launch.
- EBITDA climbed 39%, outpacing revenue growth.
- Capacity expansion is key, with new lines planned.
OneSource Specialty Pharma achieved a robust start to FY 2027, announcing a 37% year-over-year revenue increase to INR 4,490 million for its first quarter. The company's performance was propelled by the semaglutide launch within its drug-device combination segment, alongside new customer wins and enhanced product mix. EBITDA rose by 39% to INR 1,233 million, signaling strong operating leverage.
Demand for semaglutide is reportedly outstripping supply, with the company manufacturing over 40% of generic pens sold in India as of June 26. Management reaffirmed its FY 2028 outlook, projecting INR 400 million in organic revenue and a 40% EBITDA margin. Key to future growth is an ongoing capacity expansion, including new cartridge lines and injectable upgrades.
The company experienced steady market reaction, with shares trading largely unchanged. Looking ahead, OneSource Specialty Pharma is focused on executing its capacity expansion plans, with several new lines scheduled for commercialization throughout FY 2027 and into FY 2028. Biologics commercial revenue is anticipated from FY 2029 onwards.
